Medicare's $50 GLP-1 copay: how the Bridge program actually works
Medicare's Bridge program caps certain weight-loss GLP-1s at a flat $50 a month through 2027. Here is who qualifies, which drugs count, and the fine print your plan will not volunteer.
Where the $50 comes from
The Medicare GLP-1 Bridge program launched July 1, 2026. It grew out of the pricing agreements the White House announced with Novo Nordisk and Eli Lilly on November 6, 2025. Participating Part D plans now cover certain GLP-1 drugs prescribed for weight management at a flat $50 monthly copay, at every dose level. Under the deals, the drugmakers accept a net price of about $245 a month from Medicare for these prescriptions. The program runs through December 31, 2027.
That is the whole pitch. The details below are where people get tripped up.
Who qualifies
Three gates. You must be enrolled in Part D, either a standalone drug plan or drug coverage through Medicare Advantage. Your plan must participate in the Bridge program; participation is not universal. And you must meet the program's medical criteria, with a prescription written for weight management. KFF estimates roughly 3.8 million beneficiaries could qualify. Approval is not automatic; expect prior authorization.
Which drugs are in, and which are not
In, at $50 for all doses: Wegovy injection pens, Wegovy pills (oral semaglutide), Foundayo (orforglipron) tablets, and the Zepbound KwikPen. Zepbound single-dose vials are not included; only the KwikPen is.
Not in: Ozempic and Mounjaro prescribed for weight loss. They are not FDA-approved for weight loss, and the Bridge program does not change that. If you take Ozempic or Mounjaro for type 2 diabetes, nothing changes either; that is ordinary Part D coverage with your plan's normal cost sharing, entirely separate from this program.
The fine print on the $50
The $50 does not count toward your Part D deductible, and it does not count toward the $2,100 annual out-of-pocket cap. If you take other expensive drugs, Bridge copays will not move you toward the cap faster. Budget the $50 as a standalone expense, $600 a year, on top of everything else you pay.
How to ask your plan
Call the number on your member card and ask two questions. First: "Does this plan participate in the CMS GLP-1 Bridge program, and is my drug on the Bridge list at the $50 copay?" Second: "What does the prior authorization require, and how long does approval take?" Get answers in writing through your plan portal if you can.
If your plan does not participate, you can compare participating plans during fall open enrollment, October 15 to December 7, for 2027 coverage.
What happens after 2027
Nobody knows. The Bridge program sunsets December 31, 2027. CMS has indefinitely postponed the broader pilot that was supposed to follow it, extended the Bridge by a year instead, and says it will use utilization data from the program to decide what comes next. Treat the $50 as temporary until proven otherwise. If the price reverting in 2028 would change your plans, that is a conversation to have with your prescriber now, not in December 2027.
Run the numbers anyway
A flat $50 is very hard to beat, and for included drugs it almost always wins. But compare honestly instead of assuming. The cheapest widely available cash price right now is the Wegovy pill at $149 a month for the 1.5 mg dose through Novo's own retail cash program. Against that, the $50 copay still wins by about $1,200 a year. Cash prices for injectable pens run higher still — the full picture is in our True-Cost Index.
The comparison matters most in reverse. If you do not qualify for the Bridge program, do not pay list price; manufacturer cash programs exist and beat coupons for these drugs. And if the Bridge dies after 2027, that $149 pill price is the fallback worth knowing about today.
eDietAdvice may earn a commission when you use links on this page; commissions never affect the prices we report or how we rank options. This is pricing journalism, not medical advice.